my videos of product knowledge

Tuesday, 19 June 2012

Nectarines, Plums And Peaches May Fight Obesity And Diabetes

Stone fruits, also known as drupes, such as nectarines, plums and peaches, may contain useful compounds that help fight-off metabolic syndrome, which can lead to diabetes, heart attack and stroke, say researchers from Texas AgriLife Research, a member of Texas A & M University System.
Food scientist, Luis Cisneros-Zevallos and team showed that compounds that exist in stone fruits could be useful in the fight against metabolic syndrome, in which inflammation and obesity eventually lead to serious illnesses and health problems.
The scientists will present their findings at the American Chemical Society in Philadelphia in August, 2012.
Cisneros-Zevallos said:
"In recent years obesity has become a major concern in society due to the health problems associated to it. In the U.S., statistics show that around 30% of the population is overweight or obese, and these cases are increasing every year in alarming numbers."
Everyone now knows that diet, genetics, lack of sleep, and physical inactivity play a major role in the obesity epidemic. The main concern is obesity's association with metabolic syndrome. Metabolic syndrome is a collection of conditions, including high blood sugar levels, hypertension (high blood pressure), too much fat around the waist, and excessively highcholesterol levels - together, they considerably raise the risk of developing diabetes, having astroke, or a heart attack.
Cisneros-Zevallos said:
"Our studies have shown that stone fruits - peaches, plums and nectarines - have bioactive compounds that can potentially fight the syndrome.
Our work indicates that phenolic compounds present in these fruits have anti-obesity, anti-inflammatory and anti-diabetic properties in different cell lines and may also reduce the oxidation of bad cholesterol LDL which is associated to cardiovascular disease."
NIEdot325
Stone fruits (drupes) have a mixture of bioactive compounds that work together and attack different components of metabolic syndrome.
Cisneros-Zevallos explained:

"Our work shows that the four major phenolic groups - anthocyanins, clorogenic acids, quercetin derivatives and catechins - work on different cells - fat cells, macrophages and vascular endothelial cells. They modulate different expressions of genes and proteins depending on the type of compound.
However, at the same time, all of them are working simultaneously in different fronts against the components of the disease, including obesity, inflammation, diabetes and cardiovascular disease."

The researchers say that this is the first time bioactive compounds from a fruit have been demonstrated to have the potential to attack a disease from several different fronts.
Zevallos said "Each of these stone fruits contain similar phenolic groups but in differing proportions so all of them are a good source of health promoting compounds and may complement each other."
The scientists now plan to determine what the role each type of compound has, at a molecular level. They also wish to confirm their animal studies.
Written by Christian Nordqvist

Saturday, 16 June 2012

Virus Hitches Ride On Blood Cells To Kill Cancer

Scientists have discovered when a cancer-killing virus is injected in the bloodstream it hitches a ride on blood cells and evades attack from the immune system, allowing it to reach cancer tumors, and start destroying cancer cells. They suggest this means it may be possible to use promising "viral therapy" during routine outpatient sessions, like chemotherapy, to treat a wide range ofcancers.
Certain viruses, like the reovirus, that causes colds and mild stomach upsets, prefer to attack cancer cells. They also stimulate the immune system to attack tumors.
Using these "oncolytic" viruses to kill cancer is a fairly new approach that is currently being tested. Trials are currently under way to test "viral therapy" as an approach to treat cancer in human patients.
But the challenge is how to get the viruses into tumors without alerting the immune system to destroy them. One way is to inject them into the tumors, but this is technically difficult and particularly so for tumors that are deep inside the body, such as in the lungs, stomach, liver and pancreas.
Another way could be to inject the virus into the bloodstream; however, scientists have assumed this would not be feasible because the virus would likely be spotted and destroyed by the immune system before it could reach the tumor.
But when a group of scientists decided to test this by injecting the virus into the bloodstream of patients with advanced colorectal cancer, they found the virus was able to evade the immune system by "going under cover" and hitching a ride on red blood cells.
The study, led by researchers from the University of Leeds and The Institute of Cancer Research (ICR) in the UK, reveals how the "hitch-hiking" virus is shielded from antibodies in the bloodstream that might otherwise neutralize its anti-cancer properties.
The team writes about its work in a paper published online in Science Translational Medicineon 13 June.
The study participants were 10 patients with advanced colorectal cancer that had spread to the liver and who were scheduled to undergo surgery on the secondary tumors in their livers.
In the weeks leading up to their surgery, all patients received up to five doses of the reovirus as outpatients.
From blood samples taken shortly after treatment, the researchers found that the active virus associated with blood cells. Later samples showed the virus was no longer in the blood cells and had quickly cleared from the system.
When the researchers examined samples of liver tissue removed during surgery up to four weeks later, they found "viral factories" and active virus in the tumor samples but not in normal tissue samples. This confirmed the virus had travelled specifically to the tumor after being injected into the bloodstream.
Professor Alan Melcher of the University of Leeds, and Dr Kevin Harrington from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, jointly led the study.
Melcher told the press:
"It seems that reovirus is even cleverer than we had thought. By piggybacking on blood cells, the virus is managing to hide from the body's natural immune response and reach its target intact. This could be hugely significant for the uptake of viral therapies like this in clinical practice."
Harrington commented that:
"Viral treatments like reovirus are showing real promise in patient trials. This study gives us the very good news that it should be possible to deliver these treatments with a simple injection into the bloodstream," he added.
He said if these treatments could only be delivered by injecting into the tumor, they would have limited use, but discovering that the virus "can hitch a ride on blood cells will potentially make them relevant to a broad range of cancers".
"We also confirmed that reovirus was specifically targeting cancer cells and leaving normal cells alone, which we hope should mean fewer side-effects for patients," said Harrington.
Funds from Cancer Research UK, Leeds Experimental Cancer Medicine Centre, University of Leeds, The Institute of Cancer Research, Leeds Cancer Vaccine Appeal, and the Rays of Hope Appeal, paid for the study.
Written by Catharine Paddock PhD

MRK logo

Thursday, 14 June 2012

From Infection To Inflammation To Cancer: Scientists Offer New Clues

Article Date: 14 Jun 2012 - 0:00 PDT

Chronic inflammation of the liver, stomach or colon, often as a result of infection by viruses and bacteria, is one of the biggest risk factors for cancer of these organs. Scientists at the Massachusetts Institute of Technology (MIT) in the US have been researching this for over three decades, and now in a new paper published online this week they offer the most comprehensive clues so far about the potential underlying molecular mechanisms.
A bacterium called Helicobacter pyloricauses stomach ulcers and cancer in humans. Helicobacter hepaticus has a similar effect in mice, so the researchers used it as a model to study how such a bacterial infection alters genes and chemicals in the liver and colon.
They write about their findings in a paper that appeared online in the 11 June issue of theProceedings of the National Academy of Sciences, PNAS.
One of the four senior authors of the paper is Peter Dedon, a professor of biological engineering at MIT. Biological engineering is where molecular life scientists work with engineers to discover how biological systems function; the resulting knowledge can be used to develop new medical technologies.
Dedon and his co-authors hope their findings will help other researchers develop ways to predict the health problems caused by chronic inflammation and design drugs to stop it.
"If you understand the mechanism, then you can design interventions," he said in a statement. "For example, what if we develop ways to block or interrupt the toxic effects of the chronic inflammation?"
Inflammation is a natural body reaction to an infection or wound, but if the inflammation persists too long, it can damage healthy tissue.
A study published recently in The Lancet found that inflammation caused by infections account for around 16% of new cancer cases worldwide.
Inflammation begins when the immune system detects cell damage or pathogens: both of these are potential threats to health. This triggers a surge of immune cells called macrophages and neutrophils that come along to clean up and remove the threat. They engulf the invading organisms, dead cells, debris and materials released by dead or damaged cells, such as proteins, nucleic acids and other molecules.
As well as removing these materials, the immune cells produce highly reactive chemicals to break down the bacteria. And it appears that it is this part of the process that is linked to cancer risk, because, as Dedon explained, "in engulfing the bacteria and dumping these reactive chemicals on them, the chemicals also diffuse out into the tissue".
If the inflammation persists, the tissue is constantly bathed in the reactive chemicals.
For the new study, which was funded by the National Cancer Institute, Dedon and colleagues studied mice infected with H. hepaticus for 20 weeks. After 10 weeks, the mice developed severe colitis and hepatitis, and at 20 weeks, some had also developed colon cancer.
Over the 20 weeks they examined the tissue damage in the mice, and assessed damage to DNA, RNA and proteins. They also identified which genes were switched on and off.
They found that levels of one of the damaged products in DNA and RNA, chlorocytosine, correlated well with the severity of the inflammation. This could serve as a marker to predict the risk chronic inflammation in patients with infections in the colon, liver or stomach, said the researchers.
But Dedon said this does not necessarily mean you could use such a marker to predict the risk for cancer from these damaged molecules.
The researchers also noticed that the liver responded differently to the colon.
When DNA of healthy tissue comes under attack, it triggers a mechanism that attempts to repair the DNA. The researchers found that DNA repair was more active in the liver than in the colon, even though both experienced DNA damage.
Another difference was that in the colon, but not the liver, neutrophils released hypochlorous acid (a constituent of household bleach). This acid causes significant damage to molecules like DNA, RNA and proteins by attaching a chlorine atom. It is an effective way to kill bacteria, but if the acid leaks into surrounding tissue, it can cause similar damage to the epithelial cells in the lining of the colon.
Dedon said:
"It's possible that we have kind of a double whammy [in the colon]. You have this bacterium that suppresses DNA repair, at the same time that you have all this DNA damage happening in the tissue as a result of the immune response to the bacterium."
The team also identified two other unknown types of DNA damage, the molecules spiroiminodihydantoin and guanidinohydanotoin, which result from oxidation of guanine, a building block of DNA.
They now plan to look at the mechanisms more closely, for instance to find out why some types of DNA damage are more frequent than others.
Written by Catharine Paddock PhD

3e8a543692bc0821992b8a0d77b2fece MRK logo

Sunday, 27 May 2012

Lack of Sleep Is Linked to Obesity, " New Evidence Shows "

obese-child-sleeping

Q - Can lack of sleep make you fat ?
A new paper which reviews the evidence from sleep restriction studies reveals that inadequate sleep is linked to obesity. The research, published in a special issue of the The American Journal of Human Biology, explores how lack of sleep can impact appetite regulation, impair glucose metabolism and increase blood pressure.
Obesity develops when energy intake is greater than expenditure. Diet and physical activity play an important part in this, but an additional factor may be inadequate sleep," said Dr Kristen Knutson, from the University of Chicago. "A review of the evidence shows how short or poor quality sleep is linked to increased risk of obesity by de-regulating appetite, leading to increased energy consumption."
>> The studies revealed how signals from the brain which control appetite regulation are impacted by experimental sleep restriction. Inadequate sleep impacts secretion of the signal hormones ghrelin, which increases appetite, and leptin, which indicates when the body is satiated. This can lead to increased food intake without the compensating energy expenditure.

3e8a543692bc0821992b8a0d77b2fece MRK logo

Sperm Gene Discovery May Lead To Non-Hormonal Male Contraceptive

563053-36129-6 

The discovery of a gene that enables sperm to mature may lead to the development of a non-hormonal male contraceptive, according to new research in mice, led by the University of Edinburgh, Scotland, that was published in the journalPLoS Genetics on 24 May.
Currently, the only male contraceptives available rely on disrupting the production of hormones like testosterone, which can cause unpleasant side effects such as acne, irritability and mood swings.
First author Dr Lee Smith is Reader in Genetic Endocrinology at the University of Edinburgh's Centre for Reproductive Health. He told the media:
"If we can find a way to target this gene in the testes, we could potentially develop a non-hormonal contraceptive."
The gene, called Katnal1, is critical to enabling sperm to mature in the testes.
Finding a way to regulate the gene could potentially stop the sperm maturing and render them ineffective.
Not only could this form the basis of a new type of male contraceptive that does not involve disrupting hormone levels, it could also lead to new treatments for male infertility caused by a faulty Katnal1 gene.
"The important thing is that the effects of such a drug would be reversible because Katnal1 only affects sperm cells in the later stages of development, so it would not hinder the early stages of sperm production and the overall ability to produce sperm," explained Smith.
"Although other research is being carried out into non-hormonal male contraceptives, identification of a gene that controls sperm production in the way Katnal1 does is a unique and significant step forward in our understanding of testis biology," he added.
The production and maturation of sperm cells is a complex process that relies on key interactions between germ cells and supporting mechanisms, including a "scaffolding" structure made of microtubules that allows nutrients and other compounds essential to sperm health and growth to travel to the germ cells.
The authors write that it is well established that an essential component of male fertility is a process that breaks down and rebuilds the microtubules, which allows the sperm cells to move within the testes as they mature.
But until now, nobody knew which gene was responsible for this process.
In their study, Smith and colleagues discovered that when they knocked out the Katnal1 gene in male mice it rendered them infertile.
They found that Katnal1 is expressed in the testicular Sertoli cells (SC) that support germ cell maturation and that "consistent with chemical disruption models, loss of function of KATNAL1 leads to male-specific infertility through disruption of SC microtubule dynamics and premature exfoliation of spermatids from the seminiferous epithelium".
Thus they established that Katnal1 is the essential controller of the process that regulates the microtubule scaffolding structure.
In their discussion, Smith and colleagues describe Katnal1 as an essential promoter of male fertility, and discovering how it behaves within the testicular Sertoli cells "represents an important first step towards understanding the molecular mechanisms underlying SC microtubule remodelling".
"Such information will be of utility both for increasing our understanding of male infertility and the development of treatments and non-hormonal male contraceptives," they conclude.
Grants from the UK Medical Research Council and the National Health and Medical Research Council of Australia helped finance the study.
Written by Catharine Paddock PhD

3e8a543692bc0821992b8a0d77b2fece MRK logo

Saturday, 26 May 2012

Jet Device Injects Drugs Without Needles

The prospect of less painful medicine shots without needles came a step closer this month, as US researchers revealed how they have developed a device that delivers a controlled, tiny, high-pressure jet into the skin without using a hyperdermic needle.
While there are already several jet-devices on the market, they tend to be of an "all or nothing" design that delivers the same amount of drug to the same depth each time.
However the new jet-injection device that researchers at MIT have engineered can be programmed to deliver medicine into the skin in a range of doses to variable depths in a controlled manner.
A statement released earlier this week gives details of the new technology, with comments from study leader Ian Hunter, the George N. Hatsopoulos Professor of Mechanical Engineering at MIT, and some members of his team. Earlier this year, the journal Medical Engineering & Physics also published a paper where they describe the progress of their development.
Hunter and colleagues see a number of advantages to the technology.
One advantage is a reduction in needle-stick injuries. For instance, according to the US Centers for Disease Control and Prevention (CDC), there are around 385,000 cases a year in the US of health workers in hospitals accidentally pricking themselves with needles.
Another advantage of a needle-less device is it may help improve compliance, for instance among diabetes patients who are reluctant to use hyperdermic needles to inject themselves with insulin.
Team member Catherine Hogan is a research scientist in MIT's Department of Mechanical Engineering. She said:
"If you are afraid of needles and have to frequently self-inject, compliance can be an issue."
"We think this kind of technology ... gets around some of the phobias that people may have about needles," she added.
Scientists have been working for some time to find alternatives to the hypodermic needle. For instance, nicotine patches are one example of how to release drugs through the skin. But there is a limit to the size of the molecule you can use in a patch: it has to be small enough to pass through the pores of the skin, which rules out larger protein-based drugs, for instance, which are increasing in use.
A jet injector device delivers a high-velocity jet that penetrates the skin. But while these are commercially available, many have spring-loaded designs, they are all limited by the fact they deliver the same amount of drug each time to the same depth of skin.
But thanks partly to a "custom high-stroke linear Lorentz-force motor that is feed-back controlled during the time-course of an injection", the MIT jet injector can deliver a range of doses to variable depth in a highly controlled manner.
The feed-back control aspect of it allows the device to react in "real time" and adjust itself accordingly to meet the programmed instruction.
The Lorentz-force motor is essentially a small, powerful magnet surrounded by a wire coil attached to a piston located inside a drug ampoule.
When an electric current passes through the coil it produces a magnetic field that forces the piston forward, ejecting the drug at very high pressure and speed (nearly as fast as the speed of sound) through the nozzle of the ampoule, which is about the same thickness as the proboscis of a mosquito.
The researchers have shown how using this device, they can monitor and modulate continuously the speed of the drug jet, and "regulate precisely the volume of drug delivered during the injection process", as they write in their paper.
They also report being able to control injection depth up to 16 mm, and "repeatably and precisely inject volumes of up to 250 μL into transparent gels and post-mortem animal tissue".
By controlling the amount of current, the researchers control the speed and pressure. They have generated pressure profiles that modulate the current.
There is a high-pressure phase that ejects drug at a speed sufficient to "breach" the skin and reach the desired depth, and there is a lower-pressure phase that delivers drug in a slower stream that can easily be absorbed by the surrounding tissue.
From tests, the team established that different skin types may require different pressures to deliver the right volume to the right depth in the skin, as Hogan explained:
"If I'm breaching a baby's skin to deliver vaccine, I won't need as much pressure as I would need to breach my skin."
"We can tailor the pressure profile to be able to do that, and that's the beauty of this device," she added.
The team is also developing a version of the device that delivers drugs normally dispensed in powdered form: by programming the device to vibrate, the powder becomes "fluidized" and can penetrate the skin like a liquid.
This version would be very useful in situations where there is risk of a "cold chain" problem. This problem is not uncommon in developing countries, where whole batches of drugs and vaccines have to be destroyed if they can't continuously be kept refrigerated in liquid form.
Written by Catharine Paddock PhD

3e8a543692bc0821992b8a0d77b2fece MRK logo

Friday, 25 May 2012

Calcium Supplements May Increase Heart Attack Risk

Article Date: 24 May 2012 - 12:00 PDT

An analysis of data on nearly 24,000 people followed for over a decade suggests taking calcium supplements may increase the risk of having a heart attack. This is the main finding of a study published online this week in the journal Heart that also concludes boosting overall calcium intake through dietary sources brings no significant benefit in terms of reducing risk of heart disease or stroke.
The researchers say calcium supplements, which are often recommended to the elderly and women after the menopause to protect against bone thinning, should be "taken with caution". Some experts are saying we should wait for further research to corroborate these findings before acting on this advice, and people who take supplements who are concerned should talk to their doctor.
The findings also appear to go against previous studies that have shown a higher calcium intake is linked to a lower risk of a number of conditions that predispose to heart disease and stoke, namely high blood pressure, obesity, and type 2 diabetes.
The study is based on data collected on participants who were aged 35 to 64 years old between 1994 and 1998 when they joined one of the German arms of the EPIC (European Prospective Investigation into Cancer and Nutrition) study in Heidelberg.
At the start of the study the participants filled in questionnaires that assessed their diet for the previous 12 months, and they also answered questions about regular intake of vitamin and mineral supplements.
Their health was followed for an average of 11 years afterwards. During this time, the group experienced 354 heart attacks and 260 strokes, and 267 participants died of related causes.
When they analyzed the results, the researchers ranked them according to levels of calcium intake, and examined them from various points of view, such as calcium intake including supplements, and the effect of supplements alone. They also adjusted them to remove as far as possible effects from other known influencing factors.
They found participants with a moderate intake of calcium from all sources (820mg a day, including supplements) had a 31% lower risk of heart attack than the ones in the bottom 25% of calcium intake.
But those who calcium intake from all sources, including supplements, was higher than 1,100mg a day did not have a significantly lower risk of heart attack than the bottom intake group.

Plus, the researchers found no link between raised or lowered risk of stroke for any level of calcium intake from all sources, which they say reflects the findings of other studies.
However, when they looked at the results for supplements only, they found the participants who took calcium supplements on a regular basis had an 86% higher risk of having a heart attack than those who did not take any supplements at all.
And for participants who only took calcium supplements (that is no other vitamins or mineral supplements), this figure shot up: they had more than double the risk of having a heart attack compared with those who took no supplements at all.
The researchers conclude that their findings suggest:
"... increasing calcium intake from diet might not confer significant cardiovascular benefits, while calcium supplements, which might raise [heart attack] risk, should be taken with caution."
The study has drawn a mixed response, with some saying it adds to those that are questioning the safety of calcium supplements, and others pointing to the study's limitations and calling for further studies to corroborate the findings.
In an editorial in the same issue of the journal, Professors Ian Reid and Mark Bolland from the Faculty of Medical and Health Science at the University of Auckland in New Zealand, write that calcium supplements are "now coming under increasing scrutiny".
They refer to studies that link them to kidney stones and problems with the gut and abdominal symptoms. They also point out that while there is evidence that they reduce levels of cardiovascular risk factors, this does not actually translate into reduction in heart attacks and strokes.
Another point they make is that women who take calcium supplements to protect against bone thinning are already healthier than the women who do not, and the effect is modest anyway, around 10% only.
They say dietary calcium is helpful because it is taken in small amounts that are absorbed throughout the day, whereas supplements tend to be taken all in one go, causing blood calcium levels to spike above normal, and it is this that causes harm, they suggest.
"It is now becoming clear that taking this micronutrient in one or two daily [doses] is not natural, in that it does not reproduce the same metabolic effects as calcium in food," they write, suggesting we should discourage taking supplements to boost calcium intake.
"We should return to seeing calcium as an important component of a balanced diet, and not as a low cost panacea to the universal problem of postmenopausal bone loss," they conclude.
Natasha Stewart, Senior Cardiac Nurse with the British Heart Foundation, said while this study suggests there may be an increased risk of having a heart attack for people who take calcium supplements, it doesn't mean the supplements cause heart attacks. She told the press:
"Further research is needed to shed light on the relationship between calcium supplements and heart health. We need to determine whether potential risks of the supplements outweigh the benefits calcium can give sufferers of conditions such as osteoporosis."
"If you've been prescribed calcium supplements, you should still keep taking your medication, but speak to your doctor if you have any concerns," she added.
This study was published in the journal Heart.
The supplement industry expresses a similar view. Dr Taylor C. Wallace is Senior Director for Scientific & Regulatory Affairs at The Council for Responsible Nutrition (CRN) in the US. He said in a statement issued from Washington on Wednesday that "the study itself is not reason enough to discount the important benefits of calcium".
He urges consumers with questions, and their doctors, to consider some of the study's limitations, for instance the fact it was not originally designed to measure cardiovascular events, so confounding factors were not distributed equally through the groups. As an example he points to the fact the calcium supplement group had more people with high cholesterol and more long-term smokers.
Wallace said consumers like the elderly who are at greater risk of falls and fractures due to weak bones, need calcium, and removing it from their diet could increase their risk of these problems.
"Our advice is for consumers to be aware of how much calcium they get from their diet, supplement with calcium if needed, and check with their doctor or other healthcare practitioner to determine their own personal needs," he urged.
Written by Catharine Paddock PhD

3e8a543692bc0821992b8a0d77b2fece MRK logo